ProMIS Neurosciences (PMN) Competitors

ProMIS Neurosciences (NASDAQ:PMN) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Does the MarketBeat Community prefer PMN or SGMT?

Sagimet Biosciences received 23 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 96.43% of users gave Sagimet Biosciences an outperform vote.

Company	Underperform	Outperform
ProMIS Neurosciences	Outperform Votes 4 100.00%	Underperform Votes No Votes
Sagimet Biosciences	Outperform Votes 27 96.43%	Underperform Votes 1 3.57%

Do institutionals and insiders hold more shares of PMN or SGMT?

50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 4.4% of ProMIS Neurosciences shares are owned by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is PMN or SGMT more profitable?

Sagimet Biosciences' return on equity of -23.63% beat ProMIS Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProMIS Neurosciences	N/A	-636.20%	-130.32%
Sagimet Biosciences	N/A	-23.63%	-22.91%

Which has more risk & volatility, PMN or SGMT?

ProMIS Neurosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Which has preferable earnings & valuation, PMN or SGMT?

ProMIS Neurosciences has higher earnings, but lower revenue than Sagimet Biosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMIS Neurosciences	N/A	N/A	-$13.21M	-$0.03	-20.66
Sagimet Biosciences	$2M	52.91	-$27.88M	-$1.43	-2.41

Does the media prefer PMN or SGMT?

In the previous week, Sagimet Biosciences had 2 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 3 mentions for Sagimet Biosciences and 1 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 1.89 beat Sagimet Biosciences' score of 0.89 indicating that ProMIS Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
ProMIS Neurosciences	Very Positive
Sagimet Biosciences	Positive

Do analysts recommend PMN or SGMT?

ProMIS Neurosciences presently has a consensus price target of $6.00, indicating a potential upside of 867.90%. Sagimet Biosciences has a consensus price target of $22.40, indicating a potential upside of 549.28%. Given ProMIS Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe ProMIS Neurosciences is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMIS Neurosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sagimet Biosciences	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Sagimet Biosciences beats ProMIS Neurosciences on 10 of the 16 factors compared between the two stocks.